Today: 23 June 2026
Browse Category

Pharmaceuticals 16 January 2026 - 19 January 2026

AbbVie is acquiring Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal is expected to close in the third quarter and will bring AbbVie zumilokibart, an experimental long-acting drug for atopic dermatitis and other immune diseases. Apogee claims its top eczema drug could significantly reduce injection frequency compared to Dupixent, with Phase 3 trials planned for this year. Pfizer shares declined over the past week after CFO Dave Denton announced he will step down in August, with Cecile Guegan set to become interim CFO. Despite the leadership change, Pfizer maintained its 2026 forecast, but investors remain focused on succession, execution, and competition from obesity-drug makers. Pfizer’s stock has also been affected by concerns over pricing pressure, patent cliffs, and a longer path to profitability in obesity drugs. Meanwhile, Novo Nordisk shares rose about 5% as healthcare stocks gained favor among investors seeking defensive positions, even as the company reported strong demand for its Wegovy pill. Alumis shares surged 15.55% ahead of Phase 2b lupus results due in the third quarter and a planned psoriasis NDA filing in the fourth quarter. Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted application for ONS-5010/LYTENAVA, with a key FDA decision expected on July 29. Other notable moves include AtaiBeckley’s 7.8% rise following the start of its BPL-003 Phase 3 program and CervoMed’s premarket jump after a director-linked trust purchased $3 million in units, following a recent $10.5 million private placement.
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab — what to watch next week

Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab — what to watch next week

Novartis shares closed up nearly 1% at 115.60 francs in Zurich after U.S. regulators granted Breakthrough Therapy status to its Sjögren’s disease drug candidate, ianalumab. The Swiss Market Index fell 0.47%. Novartis plans global submissions for ianalumab in early 2026. U.S. markets will be closed Monday for Martin Luther King Jr. Day.
18 January 2026
··
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk shares surged 6.49% to 388.90 Danish crowns Friday after early U.S. prescription data for its new Wegovy pill and UK approval of a higher Wegovy dose. U.S. retail pharmacies filled 3,071 Wegovy pill prescriptions in the first four days, not counting online sales. Novo’s ADRs rose 0.74% in New York. Investors await the company’s earnings report on Feb. 4.
18 January 2026
·
Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer shares fell 0.93% to $25.65 Friday amid industry concerns over a White House-backed fast FDA review program, Reuters reported. The company reaffirmed its 2026 revenue forecast and set its next dividend at $0.43 per share, with an ex-dividend date of Jan. 23. U.S. markets will close Monday for Martin Luther King Jr. Day. Pfizer’s quarterly results are due Feb. 3.
18 January 2026
··
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk A/S Class B shares surged 6.5% to 388.9 Danish crowns Friday in Copenhagen after early U.S. prescription data for the new Wegovy pill surfaced and Britain approved a higher Wegovy dose for certain obesity patients. Trading volume reached 13.9 million shares. IQVIA data showed 3,071 U.S. retail prescriptions for the pill in its first four days, not counting online orders.
17 January 2026
··
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly shares rose 0.5% to $1,038.40 Friday as the FDA set April 10 as the new target date for a decision on its experimental weight-loss pill. The agency delayed review timelines for several drugs, including Lilly’s, under its fast-track program. Novo Nordisk’s new Wegovy pill saw about 3,071 U.S. prescriptions in its first four days, according to IQVIA data.
17 January 2026
··
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk shares surged 6.5% in Copenhagen and 9.1% in New York after early U.S. prescription data showed 3,071 Wegovy pill scripts filled in four days. Britain approved a higher maximum dose of Wegovy for obesity patients. A Texas compounding pharmacy sued Novo and Eli Lilly over alleged market dominance. Novo called the lawsuit “without merit.”
17 January 2026
···
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK shares fell 1.7% to 1,817 pence in London Friday, extending a three-day slide and closing 11.7% below their December peak. Trading volume surged to 12.6 million shares. Filings showed senior executives reinvested dividends into shares and U.S. ADSs. Investors are awaiting GSK’s full-year results and U.S. drug-approval updates in early February.
17 January 2026
·····
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck & Co shares fell 1.9% to $108.83 Friday after a Reuters report highlighted industry concerns over the FDA’s new fast-track drug approval program. Internal FDA documents show some drug reviews have been delayed due to safety and effectiveness worries, including a patient death linked to Sanofi’s Tzield. The S&P 500 healthcare sector dropped 0.8% amid broader market weakness. Only one drug has been approved under the program so far.
17 January 2026
·····
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly shares rose 0.5% in after-hours trading after the FDA delayed its decision on the company’s obesity drug orforglipron to April 10. Lilly and Novo Nordisk face a lawsuit from Texas-based Strive Specialties, which alleges both companies restricted access to cheaper compounded versions of GLP-1 drugs. Lilly also disclosed a 10% stake in Aktis Oncology.
17 January 2026
··
Merck stock slips as FDA fast-track questions build and earnings near

Merck stock slips as FDA fast-track questions build and earnings near

Merck shares fell 1.2% to $109.65 Friday, underperforming the market as investors reacted to renewed scrutiny of the FDA’s expedited drug review program. The FDA delayed reviews of two drugs in the program after safety concerns, including a reported patient death. Merck is developing two drugs under this program and plans to report earnings on Feb. 3. About 7.6 million shares traded by the afternoon.
16 January 2026
··
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
···
1 … 14 15 16 17 18 … 42

Stock Market Today

  • Primary Health Properties Stock Faces Price Target Split Amid Divergent Analyst Views
    June 23, 2026, 2:48 AM EDT. Primary Health Properties (LSE:PHP) sees a fresh split in price target as analysts diverge on valuation. JPMorgan sets a baseline target at £1.05, aligning with consensus, while Kepler Cheuvreux initiates coverage with a bullish outlook. The fair value estimate remains steady at £1.15 per share. Bullish analysts view the £1.05 target as underpriced, pointing to potential gains reflecting long-term profitability. Cautious voices highlight the narrow gap between price target and fair value, suggesting limited upside without stronger company performance. Key financial assumptions-revenue growth at 8.65%, net profit margin near 87.55%, and a slight dip in the future price-to-earnings (P/E) multiple-remain stable. Investors are advised to monitor evolving analyst sentiment for shifts in valuation perspectives.

Latest articles

Amazon Stock Just Got Hit Before Prime Day — AI Spending Fears Are Back

Amazon Stock Just Got Hit Before Prime Day — AI Spending Fears Are Back

23 June 2026
Amazon shares plunged 4.75% to $232.79 as investors questioned whether the company’s massive AI and cloud spending will pay off quickly enough, just ahead of Prime Day—a key test of U.S. consumer demand—with Bank of America projecting $21.6 billion in sales for the event and analysts warning that profit quality could disappoint if shoppers focus on lower-margin essentials.
Keel Shares Hit Record—What’s Next for the Stock

Keel Shares Hit Record—What’s Next for the Stock

23 June 2026
Keel Infrastructure Corp. surged 5.9% to a 52-week high as investors bet its power sites can be converted to AI data-center leases, with shares ending at $6.66 on heavy volume; the stock’s rally now hinges on permits, construction, and landing customer contracts, while upcoming Russell 3000 index inclusion and recent $458 million convertible note financing add both opportunity and dilution risk.
Go toTop